We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
501
DELISTED
Cymabay Therapeutics
CBAY
| $1.73M | 0.02% |
338,000
-40,000
| -11% | -$242K |
|
|
NATI
502
DELISTED
National Instruments Corp
NATI
| $1.72M | 0.02% |
40,898
-70,938
| -63% | -$3.04M |
|
503
Pacific Biosciences
PACB
$422M
| $1.71M | 0.02% |
331,355
-2,000
| -0.6% | -$11.2K |
|
504
Raymond James Financial
RJF
$33.3B
| $1.69M | 0.02% |
30,777
-24,527
| -44% | -$1.33M |
|
505
Chipotle Mexican Grill
CMG
$42.6B
| $1.68M | 0.02% |
100,200
+11,000
| +12% | +$175K |
|
506
Equifax
EFX
$20.8B
| $1.68M | 0.02% |
11,951
+425
| +4% | +$59.9K |
|
507
Diamondback Energy
FANG
$55.1B
| $1.66M | 0.02% |
18,470
-25,772
| -58% | -$2.56M |
|
508
Brown-Forman Class B
BF.B
$12.6B
| $1.64M | 0.02% |
26,115
-2,704
| -9% | -$158K |
|
509
Vulcan Materials
VMC
$36.9B
| $1.64M | 0.02% |
10,822
+267
| +3% | +$37.7K |
|
510
Alaska Air
ALK
$5.3B
| $1.63M | 0.02% |
+25,137
| New | +$1.58M |
|
|
PXD
511
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.63M | 0.02% |
12,974
+21
| +0.2% | +$2.78K |
|
512
Manulife Financial
MFC
$73.2B
| $1.6M | 0.02% |
87,463
+26,779
| +44% | +$473K |
|
513
Intellia Therapeutics
NTLA
$1.49B
| $1.6M | 0.02% |
120,000
| – | – |
|
514
Hormel Foods
HRL
$14.3B
| $1.6M | 0.02% |
36,489
+3,219
| +10% | +$135K |
|
515
IDEX
IEX
$16.6B
| $1.59M | 0.02% |
9,714
+415
| +4% | +$68.9K |
|
516
Cardinal Health
CAH
$53.7B
| $1.58M | 0.02% |
33,565
+6,594
| +24% | +$301K |
|
517
Pultegroup
PHM
$24.9B
| $1.58M | 0.02% |
43,276
+14,397
| +50% | +$479K |
|
518
Bath & Body Works
BBWI
$4.13B
| $1.58M | 0.02% |
99,858
+22,099
| +28% | +$390K |
|
519
Idexx Laboratories
IDXX
$43.9B
| $1.58M | 0.02% |
5,795
-379
| -6% | -$105K |
|
520
Methanex
MEOH
$4.19B
| $1.56M | 0.02% |
43,995
+9,680
| +28% | +$358K |
|
521
TC Energy
TRP
$71.2B
| $1.56M | 0.02% |
30,101
+3,401
| +13% | +$170K |
|
522
Federal Realty Investment Trust
FRT
$11B
| $1.52M | 0.02% |
11,159
+233
| +2% | +$30.7K |
|
|
PBCT
523
DELISTED
People's United Financial Inc
PBCT
| $1.5M | 0.02% |
95,869
+19,906
| +26% | +$311K |
|
|
XYZ
524
Block Inc
XYZ
$48.4B
| $1.49M | 0.02% |
24,104
+49
| +0.2% | +$3.33K |
|
525
Personalis
PSNL
$1.28B
| $1.48M | 0.02% |
+101,000
| New | +$1.91M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.